jump to navigation

Patient Data Shows Safe Switch from Genzyme to Shire Drug 04/08/2010

Posted by Morse Barnes-Brown Pendleton in Client News.
Tags: , ,

Shire Human Genetic TherapiesDue to the temporary closing of Genzyme’s Allston plant last summer, MBBP client Shire’s new Gaucher Disease treatment VPRIV was fast-tracked and approved by the FDA.

Shire is now reporting data from a Phase 3 study which showed that when patients switched from Genzyme’s Cerezyme to Shire’s VPRIV, in the same dosage, several key health indicators remained the same.

For more information, please visit Shire.


No comments yet — be the first.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: